Determinants of COVID-19 Pneumonia (MC-19) : Major Determinants of COVID-19 Associated Pneumonia
Molecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
ClinicalTrials.gov - (2020) vom: 19. Juni Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 14, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
---|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG00339137X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG00339137X | ||
003 | DE-627 | ||
005 | 20230425230815.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2020 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG00339137X | ||
035 | |a (UBBS_Klinische_Studien)NCT04387799 | ||
035 | |a (UBBS_Klinische_Studien)20200505 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Determinants of COVID-19 Pneumonia (MC-19) |b Major Determinants of COVID-19 Associated Pneumonia |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 14, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
520 | |a Molecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people. | ||
650 | 2 | |a Pneumonia, Bacterial | |
650 | 2 | |a Coronavirus Infections | |
650 | 2 | |a Pneumonia, Viral | |
650 | 2 | |a Pneumonia | |
650 | 2 | |a Lung Diseases | |
650 | 2 | |a Lung Diseases, Obstructive | |
650 | 4 | |a Medical Condition: Pneumonia, Viral, Pneumonia, Bacterial, Coronavirus Infection, Obstructive Lung Disease | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2020) vom: 19. Juni |
773 | 1 | 8 | |g year:2020 |g day:19 |g month:06 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04387799 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 19 |c 06 |